Conference Coverage

EULAR: Serious adverse events rise with number of biologics used in JIA

Publish date: June 12, 2015

 

AT THE EULAR 2015 CONGRESS

References

jevans@frontlinemedcom.com

Pages

Recommended Reading

TNF blocker adalimumab approved for pediatric Crohn’s disease
MDedge Rheumatology
Children born to mothers with RA more likely to be born early
MDedge Rheumatology
Juvenile idiopathic arthritis studies to look for at ACR
MDedge Rheumatology
VIDEO: BeST seeks to define best initial therapies for JIA
MDedge Rheumatology
Consent and the mature minor
MDedge Rheumatology
Best triptorelin dose identified for ovarian suppression in adolescents with lupus
MDedge Rheumatology
Managing gymnasts’ wrist and back overuse injuries
MDedge Rheumatology
Pollutants linked to disease activity in childhood-onset lupus patients
MDedge Rheumatology
PAS: Mind-body practices benefit teens with chronic illnesses
MDedge Rheumatology
NASPAG: Obesity raises unique contraceptive concerns in teens
MDedge Rheumatology